Clinical Significance of Peripheral Blood Lymphocyte Sensitivity to Glucocorticoids for the Differentiation of High-risk Patients With Decreased Allograft Function After Glucocorticoid Withdrawal in Renal Transplantation

2014 ◽  
Vol 36 (8) ◽  
pp. 1264-1272 ◽  
Author(s):  
Gulimire Muhetaer ◽  
Hironori Takeuchi ◽  
Sakae Unezaki ◽  
Shigeyuki Kawachi ◽  
Hitoshi Iwamoto ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
High Risk ◽  
Clinical Significance ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Blood Lymphocyte ◽  
High Risk Patients ◽  
Allograft Function ◽  
Risk Patients

scholarly journals Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

2021 ◽  
Author(s):  
Yan Zhang ◽  
Yuanfei Shi ◽  
Huafei Shen ◽  
Lihong Shou ◽  
Qiu Fang ◽  
...  
Keyword(s):  
T Cell ◽  
High Risk ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Blood Lymphocyte ◽  
Cell Lymphoma ◽  
Risk Group ◽  
Low Risk ◽  
Peripheral T Cell Lymphoma ◽  
Risk Patients

Abstract Background Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Its incidence rate in China is 1 to 2 times higher than in western countries. Therefore, optimal strategies for identifying high-risk patients are urgently needed. Materials and Methods We retrospectively studied 347 newly diagnosed PTCL patients from January 2011 to October 2019 and analyzed the relationship between peripheral blood lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) and prognosis. The model of Peripheral Blood Score was established to screen out high-risk patients. Results The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value based on survival rate. It was found that patients with PTCL with LMR ≤ 1.68 and PMR ≤ 300 had inferior overall survival (OS) and the difference was significant in both low-risk (P<0.001) and medium high-risk (P<0.001) groups of IPI score. In multivariate analysis, LMR ≤ 1.68 (HR=1.751, 95% CI 1.158-2.647, p=0.006), PMR ≤ 300 (HR=1.762, 95% CI 1.201-2.586, p=0.002), stage III-IV (HR=3.276, 95% CI 1.512-7.099, p=0.003), Eastern Cooperative Oncology Group (ECOG) score 3-5 (HR=2.351, 95% CI 1.647-3.356, p<0.001) and extra-nodal invasion more than one site (HR=1.659, 95% CI 1.125-2.445, p=0.039) were independently associated with short survival. LMR and PMR were integrated into "Peripheral Blood Score (PBS)" model. PTCL patients were divided into three risk groups: low-risk group, medium risk group and high-risk group. The 1-year OS was 86%, 55.3% and 22.6%, and the 3-year OS was 43.4%, 20% and 13.1%, respectively. Conclusion Overall, LMR and PMR can be used as early prognostic indicators in PTCL patients. Moreover, we can easily detect the complete blood cell count (CBC), and use PBS model to preliminarily screen and stratify patients. It is simple, convenient and accurate to screen out patients with short lives, and formulate personalized treatment strategies.

Analysis of Peripheral Blood Lymphocytes of AIDS and High-Risk Patients for Human Cytomegalovirus Transforming DNA Sequences

Intervirology ◽  
1991 ◽  
Vol 32 (1) ◽  
pp. 10-18 ◽  
Author(s):  
Abdur Razzaque ◽  
Stephen M. Peters ◽  
Edward P. Gelmann ◽  
Michael J. Sheridan ◽  
Leonard J Rosenthal
Keyword(s):  
High Risk ◽  
Human Cytomegalovirus ◽  
Dna Sequences ◽  
Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Blood Lymphocytes ◽  
High Risk Patients ◽  
Risk Patients

Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood

2002 ◽  
Vol 6 (1) ◽  
pp. 53-62 ◽  
Author(s):  
Erik Qvist ◽  
Helena Pihko ◽  
Pia Fagerudd ◽  
Leena Valanne ◽  
Sirkka Lamminranta ◽  
...  
Keyword(s):  
Early Childhood ◽  
Renal Transplantation ◽  
High Risk ◽  
Neurodevelopmental Outcome ◽  
High Risk Patients ◽  
Risk Patients

Renal transplantation in high risk patients older than sixty years

1976 ◽  
Vol 131 (6) ◽  
pp. 648-652 ◽  
Author(s):  
Roberto Tersigni ◽  
Carl M. Kjellstrand ◽  
Richard L. Simmons ◽  
John S. Najarian
Keyword(s):  
Renal Transplantation ◽  
High Risk ◽  
High Risk Patients ◽  
Risk Patients

Renal Transplantation in High-Risk Patients

Drugs ◽  
2007 ◽  
Vol 67 (11) ◽  
pp. 1603-1627 ◽  
Author(s):  
Nicole A Weimert ◽  
Rita R Alloway
Keyword(s):  
Renal Transplantation ◽  
High Risk ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1996-1996 ◽  
Author(s):  
Michael Steurer ◽  
Marco Montillo ◽  
Lydia Scarfò ◽  
Francesca Romana Mauro ◽  
Johannes Andel ◽  
...  
Keyword(s):  
Single Dose ◽  
High Risk ◽  
Partial Response ◽  
Peripheral Blood ◽  
Overall Response Rate ◽  
Response Rate ◽  
Tp53 Gene ◽  
Overall Response ◽  
High Risk Patients ◽  
Risk Patients

Abstract Background Olaptesed pegol (NOX-A12) is a novel, potent, L-stereoisomer RNA aptamer that binds and neutralizes CXCL12/SDF-1, a chemokine which attracts and activates immune- and non-immune cells via interaction with the receptors CXCR4 and CXCR7. Signaling of CXCL12 is pivotal to the interactions of leukemic cells with bone marrow microenvironment. The therapeutic concept of olaptesed is to inhibit such tumor-supporting pathways and thereby mobilizing and sensitizing CLL cells to therapy. Here we aim to assess the activity and safety of olaptesed in combination with bendamustine and rituximab (BR) in patients with relapsed / refractory CLL. Methods Twenty-eight relapsed or refractory CLL patients were enrolled and treated in this open-label, single-arm Phase IIa study. To investigate PK/PD, a pilot dose of 1 to 4 mg/kg olaptesed alone was administered to 3 patients per dose group (plus one additional replacement pt) before start of the regular treatment regimen (pilot group). Patients were treated using a dose titration design with intravenous (IV) olaptesed at doses increasing from 1 mg/kg to 2 mg/kg and 4 mg/kg at cycles 1, 2 and 3, respectively, at 1 hour before rituximab treatment. During cycles 4 to 6, olaptesed was dosed at the highest individually titrated dose. Rituximab was administered IV at doses of 375 mg/m² on day 1 of the 1st28-day cycle and 500 mg/m² on day 1 of subsequent cycles. Bendamustine (70 - 100 mg/m²) was given IV on days 2-3 (cycle 1) or days 1-2 (cycles 2-6) of each 28-day cycle following administration of rituximab. Clinical response was assessed according to NCI-WG Guidelines (Hallek M et al. Blood 111; 2008: 5446-56). Results To date, 24 patients completed treatment (12 women, 12 men) with a median age of 68.5 years (range 52 to 79). At screening 5, 9 and 10 patients presented with Binet stage A, B and C, respectively. The median number of prior treatment lines was 1 (range 1-2). Seven high-risk patients presented an unfavorable disease state being relapsed within 24 months after fludarabine/bendamustine treatment (5 pts) and/or presenting a deletion/mutation of the TP53 gene (3 pts). Most patients (19 of 24) were previously treated with fludarabine or bendamustine. A flow cytometric analysis of CD19+/CD5+CLL cells showed a rapid mobilization into the peripheral blood by a single dose of olaptesed which lasted throughout the observational time of 72h. Interestingly, CXCR4 expression levels increased on CLL cell surface in the periphery after olaptesed treatment. This increase, which peaked at 24h, likely reflects the extended circulation of CLL cells in the periphery due to the sustained blockade of CXCL12 by olaptesed. Reduction of lymphadenopathy by ≥ 50% was achieved in 14 out of 21 evaluable patients with reported enlarged lymph nodes by the end of treatment. Concomitantly, rapid reduction of lymphocytosis in peripheral blood with normalization by treatment cycle 2 – 3 was observed and the CLL to leukocyte ratio significantly improved. Efficacy was assessed at the end of cycles 3 and 6. In the full-analysis-set, which excludes two non-evaluable patients (drop-out after the 1st cycle due to adverse events), the overall response rate was 96%: Three patients (14%) achieved a complete response at end of cycle 6 (2 confirmed, 1 investigator reported) and eighteen patients (82%) achieved a partial response (fifteen at end of cycle 6 and three at end of cycle 3). Notably, all seven high-risk patients (defined as relapsed within 24 months after fludarabine/bendamustine treatment and/or presenting a deletion/mutation of the TP53 gene) responded to treatment with olaptesed + BR with a partial response. One patient had a progressive disease. Olaptesed at 1, 2 and 4 mg/kg at a single dose and in combination with BR was safe and well tolerated. The observed adverse reactions were qualitatively and quantitatively as expected for patients treated with BR. Conclusion Olaptesed in combination with BR was safe and well tolerated. Compared with historical data, olaptesed showed superiority over baseline therapy with regards to overall response rate and increasing rates of complete remission, warranting further development of this Spiegelmer in CLL. Disclosures Montillo: Janssen: Honoraria. Kruschinski:NOXXON Pharma AG: Employment. Dümmler:NOXXON Pharma AG: Employment. Riecke:NOXXON Pharma AG: Employment.

scholarly journals Decreased Peripheral Blood Lymphocyte-Monocyte Ratio and Platelet-Monocyte Ratio and the Peripheral Blood Score Model Predict Poor Survival in Peripheral T-cell Lymphoma Patients

2020 ◽  
Author(s):  
Yan Zhang ◽  
Yuanfei Shi ◽  
Huafei Shen ◽  
Lihong Shou ◽  
Qiu Fang ◽  
...  
Keyword(s):  
T Cell ◽  
High Risk ◽  
Peripheral Blood Lymphocyte ◽  
Peripheral Blood ◽  
Blood Lymphocyte ◽  
Cell Lymphoma ◽  
Risk Group ◽  
Low Risk ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma

Abstract Background. Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Its incidence rate in China is 1 to 2 times higher than in western countries. Therefore, optimal strategies for identifying high-risk patients are urgently needed. Methods. We retrospectively studied 347 newly diagnosed PTCL patients from January 2011 to October 2019 and analyzed the relationship between peripheral blood lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) and prognosis. The model of Peripheral Blood Score was established to screen out high-risk patients.Results. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value based on survival rate. It was found that patients with PTCL with LMR ≤ 1.68 and PMR ≤ 300 had inferior overall survival (OS) and the difference was significant in both low-risk (P＜0.001) and medium high-risk (P＜0.001) groups of IPI score. In multivariate analysis, LMR ≤ 1.68 (HR=1.751, 95% CI 1.158-2.647, p=0.006), PMR ≤ 300 (HR=1.762, 95% CI 1.201-2.586, p=0.002), stage III-IV (HR=3.276, 95% CI 1.512-7.099, p=0.003), Eastern Cooperative Oncology Group (ECOG) score 3-5 (HR=2.351, 95% CI 1.647-3.356, p＜0.001) and extra-nodal invasion more than one site (HR=1.659, 95% CI 1.125-2.445, p=0.039) were independently associated with short survival. LMR and PMR were integrated into "Peripheral Blood Score (PBS)" model. PTCL patients were divided into three risk groups: low-risk group, medium risk group and high-risk group. The 1-year OS was 86%, 55.3% and 22.6%, and the 3-year OS was 43.4%, 20% and 13.1%, respectively.Conclusion. Overall, LMR and PMR can be used as early prognostic indicators in PTCL patients. Moreover, we can easily detect the complete blood cell count (CBC), and use PBS model to preliminarily screen and stratify patients. It is simple, convenient and accurate to screen out patients with short lives, and formulate personalized treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document